Worldwide, it is estimated that 67% of persons aged 0-49 years are infected with herpes simplex virus type 1 (HSV-1).[2] The infection is most commonly acquired during childhood, and seropositivity increases with age. Among US adults aged 14-49 years, 47.8% are infected with HSV-1 and 11.9% are infected with HSV type 2 (HSV-2).[3] Prevalence of both HSV-1 and HSV-2 is higher among women than men. Although, overall, HSV-2 seroprevalence has declined in cross-sectional surveys, a disproportionate representation by certain at-risk populations has persisted, particularly among non-Hispanic blacks.[4] Additionally, rates of genital herpes due to HSV-1 in the US may be increasing. Worldwide, it is estimated that more than 140 million people aged 15-49 years are living with genital HSV-1, a prevalence of 4%.[2] Of STI clinic attendees, 30% to 50% are HSV-2 seropositive, and 20% to 30% of women in US antenatal clinics are HSV-2 seropositive. From 10% to 25% of HSV-2 seropositive people have a history of genital herpes lesions and most others have mild and unrecognised disease. Worldwide, HSV-2 is the most common cause of genital ulcer disease. HSV-2 infection is a risk factor for HIV-1 acquisition and transmission.[5][6] In England, HSV-2 seroprevalence in 16-64-year-olds is 9.7%.[7] Recurrence rates of genital HSV-2 are more frequent than oral-labial HSV-1 infections.[8]

BMJ Best Practice is an evidence-based point of care tool for healthcare practitioners.

To continue reading and access all of BMJ Best Practice's pages you'll need to log in or start a free trial.

You can access through your institution if your hospital, university, trust or other institution provides access to BMJ Best Practice through either OpenAthens or Shibboleth.

Use of this content is subject to our disclaimer